Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for MK-3475, Merck’s investigational anti-PD-1 antibody, for more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merck is hiring next, click here to view